Biogen Inc. (NASDAQ:BIIB - Free Report) - Investment analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for Biogen in a research report issued on Thursday, February 13th. Cantor Fitzgerald analyst E. Schmidt now expects that the biotechnology company will post earnings per share of $16.13 for the year, down from their previous forecast of $17.04. The consensus estimate for Biogen's current full-year earnings is $16.42 per share.
A number of other research analysts have also recently weighed in on the stock. Sanford C. Bernstein started coverage on shares of Biogen in a report on Tuesday, February 11th. They issued a "market perform" rating and a $160.00 price objective for the company. Morgan Stanley dropped their price objective on shares of Biogen from $192.00 to $157.00 and set an "equal weight" rating for the company in a report on Thursday, February 13th. Citigroup dropped their price objective on shares of Biogen from $160.00 to $145.00 and set a "neutral" rating for the company in a report on Thursday, February 13th. BMO Capital Markets dropped their price objective on shares of Biogen from $156.00 to $139.00 and set a "market perform" rating for the company in a report on Thursday, February 13th. Finally, Truist Financial lowered their price target on shares of Biogen from $220.00 to $210.00 and set a "buy" rating for the company in a report on Thursday, February 13th. Seventeen investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Biogen currently has a consensus rating of "Hold" and an average target price of $211.85.
Check Out Our Latest Analysis on Biogen
Biogen Trading Down 0.6 %
Shares of Biogen stock traded down $0.76 on Friday, reaching $136.57. The company had a trading volume of 1,327,009 shares, compared to its average volume of 1,414,183. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.80 and a current ratio of 1.26. The firm has a market cap of $19.90 billion, a PE ratio of 12.34, a PEG ratio of 1.65 and a beta of -0.08. The firm's 50 day moving average price is $146.52 and its two-hundred day moving average price is $172.19. Biogen has a 52-week low of $128.51 and a 52-week high of $238.00.
Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, topping analysts' consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.81% and a return on equity of 14.98%.
Hedge Funds Weigh In On Biogen
Large investors have recently bought and sold shares of the company. Larson Financial Group LLC raised its position in Biogen by 640.9% during the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company's stock worth $25,000 after buying an additional 141 shares during the last quarter. Lee Danner & Bass Inc. purchased a new position in Biogen during the 4th quarter worth $25,000. Colonial Trust Co SC raised its position in Biogen by 9,300.0% during the 4th quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company's stock worth $29,000 after buying an additional 186 shares during the last quarter. OFI Invest Asset Management purchased a new position in Biogen during the 4th quarter worth $32,000. Finally, Ashton Thomas Securities LLC purchased a new position in Biogen during the 3rd quarter worth $33,000. Hedge funds and other institutional investors own 87.93% of the company's stock.
About Biogen
(
Get Free Report)
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.
Further Reading
Before you consider Biogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.
While Biogen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
